N4 Pharma PLC Change in Director Details (7072K)
July 11 2017 - 5:31AM
UK Regulatory
TIDMN4P
RNS Number : 7072K
N4 Pharma PLC
11 July 2017
11 July 2017
N4 Pharma Plc
("N4 Pharma" or the "Company")
Change in Director Details
In accordance with Rule 17 and paragraph (g) of Schedule Two of
the AIM Rules for Companies, the Company announces that it was on
10 July 2017 notified by Paul Titley, an Executive Director of the
Company, that Critical Pharmaceuticals Limited ("Critical"), a
company of which he is a Non-Executive Director, has been placed
into creditors' voluntary liquidation. Mr Titley's authority as a
director of Critical ceased on appointment of the liquidator.
Enquiries:
N4 Pharma Via Alma PR
CEO, Nigel Theobald
Stockdale Securities Tel: +44(0)207 601
Tom Griffiths 6100
Beaufort Securities Tel: +44(0)207 382
Elliot Hance 8300
Alma PR Tel: +44(0)778 090
Josh Royston 1979
Robyn Fisher Tel: +44(0)754 070
6191
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company which
reformulates existing drugs and vaccines to improve their
performance. Its shares were admitted to trading on AIM on 3 May
2017.
N4 Pharma's reformulation work falls under two divisions:
-- generic, already commercialised, drugs; and
-- delivery of novel and existing vaccines.
N4 Pharma has identified a number of established drugs that
could be improved upon through its reformulation techniques. N4
Pharma's most advanced reformulation is for sildenafil, widely
marketed as Viagra, where N4 Pharma is seeking to improve the speed
at which the drug takes effect whilst also extending its duration
of action.
N4 Pharma's reformulation approach should take approximately
three years to obtain regulatory approval as opposed to the
traditional process for new drugs of on average ten years. The cost
and risk profile of this model is also significantly less than the
traditional process. N4 Pharma's business model is to take
reformulated drugs from its portfolio through to the stage where it
will license its newly reformulated drugs to pharmaceutical
companies to commercialise them. N4 Pharma's revenues should be
derived from up front milestone and royalty payments associated
with the licence.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAEANXFFANXEEF
(END) Dow Jones Newswires
July 11, 2017 05:31 ET (09:31 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Apr 2024 to May 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
From May 2023 to May 2024